Gene aberrations for precision medicine against lung adenocarcinoma - Test2 - elhamkhani - TriplyDB

Gene aberrations for precision medicine against lung adenocarcinoma

Gene aberrations for precision medicine against lung adenocarcinoma

http://www.wikidata.org/entity/Q26749348

about

The effect of smoking on lung cancer: ethnic differences and the smoking paradox.Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.Diagnostic MicroRNA Biomarker Discovery for Non-Small-Cell Lung Cancer Adenocarcinoma by Integrative Bioinformatics Analysis.Precision wildlife medicine: applications of the human-centred precision medicine revolution to species conservation.The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma Comprehensive epigenetic analysis of the signature genes in lung adenocarcinoma.Vinflunine for the treatment of non-small cell lung cancer.Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.EML4-ALK-positive lung adenocarcinoma presenting an unusual metastatic pattern in a 29-year-old woman who is alive and well in her third year follow up:A case report.Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma.A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer.A novel prognostic marker of non-small cell lung cancer: chromosome 9 open reading frame 86 (C9orf86).Identification of lung adenocarcinoma specific dysregulated genes with diagnostic and prognostic value across 27 TCGA cancer types.A Study on Cytotoxic and Apoptotic Potential of a Triterpenoid Saponin (3-O-α-L-Arabinosyl Oleanolic Acid) Isolated from Schumacheria castaneifolia Vahl in Human Non-Small-Cell Lung Cancer (NCI-H292) Cells.Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients.FLNa negatively regulated proliferation and metastasis in lung adenocarcinoma A549 cells via suppression of EGFR.Lidocaine inhibits the proliferation of lung cancer by regulating the expression of GOLT1A.CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells.MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.Meta-analysis of mRNA expression profiles to identify differentially expressed genes in lung adenocarcinoma tissue from smokers and non-smokers.Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma.SH2B1 promotes epithelial-mesenchymal transition through the IRS1/β-catenin signaling axis in lung adenocarcinoma.Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.Differences in MWCNT- and SWCNT-induced DNA methylation alterations in association with the nuclear deposition.Contrast-Enhanced Ultrasound Improves the Pathological Outcomes of US-Guided Core Needle Biopsy That Targets the Viable Area of Anterior Mediastinal Masses.Identification of key differentially expressed genes associated with non‑small cell lung cancer by bioinformatics analyses.Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.Targeted therapy according to next generation sequencing-based panel sequencing.Association of serum follistatin levels with histological types and progression of tumor in human lung cancer Identification of a novel therapeutic target in driver-negative non-small cell lung cancer

P2860

Q30238987-D9CC6C3A-92A1-49A1-85E2-0C1697559AE7 Q33787355-C88025EE-83CB-41F7-BC80-42FD613B7AA3 Q33862388-5DC54B71-A53C-4A5D-B5EE-E6C90E186A52 Q36181146-9E9A8FC4-378D-41E0-8AFE-8704CD6F4E48 Q37725446-1D66DA1B-4802-4A19-8CF1-60868EF49725 Q38624501-5B5CF2D8-6CAC-4462-ADE7-CF1046684E5B Q38988627-E4368A4B-1391-4F92-B58C-6CB09AD25950 Q39172334-1914080E-D5F2-4FB4-830A-061C0D1D2583 Q41492859-14B21146-D427-4A51-B141-3ACDEC4FD81A Q41612927-56A711F6-98FB-4394-9442-45C1AB68892C Q42290335-B6DC5C95-94D7-4EBE-BAB2-62E005287580 Q42384615-2D7F9CA2-59CD-4314-96F0-BED2856516EA Q46195024-270D9DF8-0711-4072-8469-3FBF85F04054 Q47096717-F8B2EE3C-20D9-4106-97FC-F4BB4436E97A Q47159292-A1F4C756-9FC2-4568-9E0E-67458E5B2B09 Q47260594-F3BA2269-4F94-4205-8A4E-9F2CE4D312FD Q47271028-2025CDDC-A627-41DC-A416-8FE15DA1BD78 Q47307445-6372443A-649E-4684-B15B-E05FB7AF5094 Q47393684-0654E130-8D3E-42F1-91BD-FBA743C7C976 Q47658633-1F615DD4-C345-43FF-BA4F-BE559EAD68A4 Q47735795-07000B96-A450-4998-ACF6-79BDE23376E1 Q48096086-E4066BDD-84A8-4AE2-AEB9-320394E2BE88 Q48520033-8ACECBB4-7A04-49A7-83B0-B88E7781019B Q48649855-E055A9F3-F710-4ACD-BBDF-CA9493208AA3 Q49537557-A437A32F-AAEE-43BB-B8F6-3EF29BBB4FD8 Q52629072-2F037823-905F-425D-A66E-3ED1F91C5D44 Q52726915-FA47E434-8F17-433A-BF1C-B0A731951740 Q54118562-051B2336-33B5-4380-9A7A-541CF3F263B6 Q55167789-3357C4F1-6CE0-4FD7-9417-05CBEF21672C Q58120657-D5185C63-DEA4-45B2-AE33-E20CA2C84CE3 Q58562470-B6CCD2BC-0005-4B52-AB9D-B440DE0984CD

P2860

Gene aberrations for precision medicine against lung adenocarcinoma

http://www.wikidata.org/entity/Q26749348

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Gene aberrations for precision medicine against lung adenocarcinoma

@ast

Gene aberrations for precision medicine against lung adenocarcinoma

@en

Gene aberrations for precision medicine against lung adenocarcinoma

@nl

type

label

Gene aberrations for precision medicine against lung adenocarcinoma

@ast

Gene aberrations for precision medicine against lung adenocarcinoma

@en

Gene aberrations for precision medicine against lung adenocarcinoma

@nl

prefLabel

Gene aberrations for precision medicine against lung adenocarcinoma

@ast

Gene aberrations for precision medicine against lung adenocarcinoma

@en

Gene aberrations for precision medicine against lung adenocarcinoma

@nl

P1433

Q26749348-AEF1C822-C760-4EB0-B31A-FBAF48A2BF6E

P1476

Q26749348-4F4805E0-3FEA-4B3C-990C-48EACE37A6F1

P2093

Q26749348-4A73F7BE-5298-4085-ADBF-BA88BB3795D3

Q26749348-A400C57E-C0AF-46A6-99B7-D91F756BD08A

Q26749348-D39600AB-FE4B-43EB-BAEB-1B1AA7B4C6A3

Q26749348-FA3920A1-0BA0-48DC-9905-6A371BF282F2

Q26749348-FB196636-8024-42FA-A932-9152D0858600

P275

Q26749348-A0267331-5687-4492-BDF9-0F08C4D87270

P2860

Q26749348-02E8E877-7512-4207-97F4-2F26AEC7C160

Q26749348-07F5DEFD-DF6A-4535-8F86-36A3BA78AB21

Q26749348-0C89DD3E-F5C6-476D-B93C-4BA94905F548

Q26749348-1290A80C-500E-40B7-ADC3-B73B4F1B242C

Q26749348-1450EA46-C98D-4547-B8FE-3D3A110ED5D5

Q26749348-1E504CD7-BCAB-4405-88FC-3E7EB3D116A5

Q26749348-210669E1-1535-4015-BEEF-F9D106A22177

Q26749348-23A2E01D-ABA6-4D04-B7BF-E26EBCB38AC2

Q26749348-2704B2E5-1FC4-42F2-9410-6CE7258B4389

Q26749348-27132A38-3120-4AE1-A396-E06AF3E2B35A

P304

Q26749348-EA35F56C-1B84-4313-B778-2EF4D3D79EA6

P31

Q26749348-94344FC6-3101-464E-ABF0-649A287E387B

P3181

Q26749348-73172696-A054-4D7B-A6BF-4E58E6E67729

P356

Q26749348-D99E6D1D-0189-4727-8060-073A87AEBE36

P407

Q26749348-BADE42A4-8F13-41A1-B6F9-342A9DB1D01C

P433

Q26749348-0101F275-E2CA-4750-BF63-10567B87656E

P478

Q26749348-66DD438A-40D5-459F-B4AC-FEF781A92194

P50

Q26749348-BCFB2F0B-D2BB-4F94-A4D3-4E8F6CCA05F2

P5008

Q26749348-7A9961A7-ACAA-4102-BEA5-9099DF505C5D

P577

Q26749348-5F324AA1-9190-47BF-8E4A-9C032C067C59

P698

Q26749348-E61C15A8-EAA9-4E72-AD70-989C66B183B5

P921

Q26749348-08BBF7AE-7658-415C-BECE-9216DC1DC18E

Q26749348-72AC3ACC-1821-4A11-A97B-18AA485DAB71

Q26749348-FF7FEB8E-46DA-402E-8811-F2FD108B2BDC

P932

Q26749348-D1032D42-A296-4A92-9121-1DE2838D17DE

P3181

P356

P1433

P1476

Gene aberrations for precision medicine against lung adenocarcinoma

@en

P2093

Hideo Kunitoh

http://www.w3.org/2001/XMLSchema#string

Jun Yokota

http://www.w3.org/2001/XMLSchema#string

Kouya Shiraishi

http://www.w3.org/2001/XMLSchema#string

Seiichi Takenoshita

http://www.w3.org/2001/XMLSchema#string

Takashi Kohno

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivatives

P2860

Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies

NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma

Characterizing the cancer genome in lung adenocarcinoma.

A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma

Molecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand Breaks

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

A patient with lung adenocarcinoma and RET fusion treated with vandetanib.

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

P304

713-720

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5003236

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/CAS.12941

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2016-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27027665

http://www.w3.org/2001/XMLSchema#string

P921

P932

4968599

http://www.w3.org/2001/XMLSchema#string